Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) VP Kimberly Gentile sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.28, for a total transaction of $146,400.00. Following the completion of the transaction, the vice president now owns 5,000 shares in the company, valued at $146,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-sells-146400-00-in-stock.html.

Several brokerages recently weighed in on BHVN. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Friday, September 8th. BidaskClub upgraded shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective (up from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. Piper Jaffray Companies restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. Finally, Morgan Stanley increased their price objective on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $40.80.

Several hedge funds and other institutional investors have recently modified their holdings of BHVN. Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $214,000. State of Wisconsin Investment Board acquired a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $262,000. Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $374,000. Strs Ohio acquired a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $680,000. Finally, American Century Companies Inc. acquired a new position in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth approximately $1,375,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.